Voclosporin is a potent, inhibitor of Calcineurin. It exhibits both immunomodulatory and non-immune effects by inhibiting T-cell proliferation, reducing proteinuria through podocyte cytoskeleton stabilization and afferent arteriole vasoconstriction, and effectively suppressing lymphocyte proliferation and cytokine production, making it useful for systemic lupus erythematosus (SLE) research.

Voclosporin is a potent, inhibitor of Calcineurin. It exhibits both immunomodulatory and non-immune effects by inhibiting T-cell proliferation, reducing proteinuria through podocyte cytoskeleton stabilization and afferent arteriole vasoconstriction, and effectively suppressing lymphocyte proliferation and cytokine production, making it useful for systemic lupus erythematosus (SLE) research.

Voclosporin is a potent, inhibitor of Calcineurin. It exhibits both immunomodulatory and non-immune effects by inhibiting T-cell proliferation, reducing proteinuria through podocyte cytoskeleton stabilization and afferent arteriole vasoconstriction, and effectively suppressing lymphocyte proliferation and cytokine production, making it useful for systemic lupus erythematosus (SLE) research.

Voclosporin is a potent, inhibitor of Calcineurin. It exhibits both immunomodulatory and non-immune effects by inhibiting T-cell proliferation, reducing proteinuria through podocyte cytoskeleton stabilization and afferent arteriole vasoconstriction, and effectively suppressing lymphocyte proliferation and cytokine production, making it useful for systemic lupus erythematosus (SLE) research.

Angiotensin II human is a potent vasoconstrictor that induces angiogenesis by activating angiotensin II type 1 (AT1) receptor, which increases the production of vascular endothelial growth factor (VEGF) in a redox-sensitive manner and promotes the formation of capillaries from endothelial cells through the LOX-1-dependent redox-sensitive pathway.

Angiotensin II human is a potent vasoconstrictor that induces angiogenesis by activating angiotensin II type 1 (AT1) receptor, which increases the production of vascular endothelial growth factor (VEGF) in a redox-sensitive manner and promotes the formation of capillaries from endothelial cells through the LOX-1-dependent redox-sensitive pathway.

Angiotensin II human is a potent vasoconstrictor that induces angiogenesis by activating angiotensin II type 1 (AT1) receptor, which increases the production of vascular endothelial growth factor (VEGF) in a redox-sensitive manner and promotes the formation of capillaries from endothelial cells through the LOX-1-dependent redox-sensitive pathway.

AH 6809 is an antagonist of EP and DP receptor, with Kis of 1217, 1150, 1597, and 1415 nM for the cloned human EP1, EP2, EP3-III, and DP receptor respectively. AH 6809 has a Ki of 350 nM for mouse EP2 receptor.

GW280264X is a potent hydroxamate inhibitor of mixed ADAM10/TACE (ADAM17). It potently blocks TACE (ADAM17) and ADAM10 with IC50s of 8.0 nM and 11.5 nM, respectively. It inhibits constitutive and PMA-inducible CX3CL1 shedding and increases adhesive properties in CX3CL1 transfected cells. Its treatment significantly improves functional recovery after spinal cord injury.

Angiotensin II human is a potent vasoconstrictor that induces angiogenesis by activating angiotensin II type 1 (AT1) receptor, which increases the production of vascular endothelial growth factor (VEGF) in a redox-sensitive manner and promotes the formation of capillaries from endothelial cells through the LOX-1-dependent redox-sensitive pathway.